Independent Research Analysts Give Merck KGaA (FRA:MRK) a €103.00 Price Target

Independent Research set a €103.00 ($119.77) price objective on Merck KGaA (FRA:MRK) in a research report report published on Thursday, September 19th, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Other analysts also recently issued research reports about the company. Nord/LB set a €94.00 ($109.30) price target on Merck KGaA and gave the company a neutral rating in a research report on Friday, August 9th. DZ Bank reiterated a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA and gave the company a neutral rating in a research report on Thursday, September 12th. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the stock a sell rating in a research report on Wednesday, August 14th. Finally, Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the stock a buy rating in a research report on Friday, September 6th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of €101.33 ($117.83).

Shares of MRK traded up €0.05 ($0.06) during trading hours on Thursday, reaching €103.90 ($120.81). 479,151 shares of the company’s stock traded hands. The firm’s 50 day simple moving average is €99.51 and its 200-day simple moving average is €95.58. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: How does a 12b-1 fee affect fund performance?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.